Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for Hepa 1-6 Cells (Hepatoma Cells, CRL-1830)
- Proprietary cationic lipids formulation
- High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, and plasmid DNA
- Effective and robust cellular delivery
- Kit includes Transfection Enhancer reagent
- A proven reagent for establishing stable cell lines
- Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download Hepa CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for Hepa cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 75% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems Hepa Transfection Protocol: [PDF]
Download MSDS: [PDF]
Hepa 1-6 Cell Line:
Liver cancer is considered the second primary cause of cancer fatalities worldwide that is responsible for more than 30,000 deaths every year in the United States. Approximately 40,000 new cases of liver cancer are diagnosed annually, as stated by the American Cancer Society. Mouse liver cells from the Hepa 1-6 hepatoma cell line are reliable transfection hosts in the study of liver disease. The Hepa 1-6 cell line is initially established from liver cells of the BW7756 mouse (Mus musculus) with hepatoma, also known as liver cancer. The cells are tumorigenic and exhibit epithelial morphology. Hepa 1-6 cells make an excellent transfection host and have been tested negative for mousepox. Also, the Hepa 1-6 cell line is widely used in biomedical research to study mammalian liver tissue functions. Altogen Biosystems provides high-efficiency lipid-based transfection reagent kits for the Hepa 1-6 hepatoma cell line.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into Hepa cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in Hepa 1-6 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into Hepa 1-6 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient cellular delivery of biomolecules (such as small proteins, DNA, mRNA, and si/shRNA). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Contract Research Services:
Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharmacology/toxicology assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6820)
- 1.5 ml (Catalog #6821)
- 1.5 ml CRISPR (Catalog #2153)
- 8.0 ml (Catalog #6822)